FABIANI, IACOPO
 Distribuzione geografica
Continente #
NA - Nord America 2.010
EU - Europa 1.768
AS - Asia 1.726
SA - Sud America 507
AF - Africa 41
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 1
Totale 6.058
Nazione #
US - Stati Uniti d'America 1.902
SG - Singapore 791
RU - Federazione Russa 615
IT - Italia 590
CN - Cina 431
BR - Brasile 418
VN - Vietnam 185
DE - Germania 107
GB - Regno Unito 97
NL - Olanda 82
CA - Canada 69
HK - Hong Kong 67
FI - Finlandia 60
TR - Turchia 51
FR - Francia 49
IN - India 40
BD - Bangladesh 38
IE - Irlanda 37
PL - Polonia 37
AR - Argentina 30
MX - Messico 29
ES - Italia 22
ID - Indonesia 22
EC - Ecuador 21
ZA - Sudafrica 21
IQ - Iraq 19
JP - Giappone 16
SE - Svezia 16
PK - Pakistan 14
IL - Israele 13
AT - Austria 12
LT - Lituania 10
UA - Ucraina 10
CO - Colombia 9
VE - Venezuela 8
BE - Belgio 7
PE - Perù 7
PY - Paraguay 7
SA - Arabia Saudita 7
AE - Emirati Arabi Uniti 6
MA - Marocco 5
UZ - Uzbekistan 5
RO - Romania 4
AU - Australia 3
DO - Repubblica Dominicana 3
EG - Egitto 3
KE - Kenya 3
KR - Corea 3
LB - Libano 3
MG - Madagascar 3
MY - Malesia 3
TT - Trinidad e Tobago 3
BO - Bolivia 2
BY - Bielorussia 2
CI - Costa d'Avorio 2
CL - Cile 2
CZ - Repubblica Ceca 2
GR - Grecia 2
HU - Ungheria 2
KG - Kirghizistan 2
KZ - Kazakistan 2
UY - Uruguay 2
AL - Albania 1
AO - Angola 1
AZ - Azerbaigian 1
BG - Bulgaria 1
CR - Costa Rica 1
CV - Capo Verde 1
CW - ???statistics.table.value.countryCode.CW??? 1
DM - Dominica 1
DZ - Algeria 1
GD - Grenada 1
GT - Guatemala 1
HR - Croazia 1
JO - Giordania 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
NO - Norvegia 1
NP - Nepal 1
PG - Papua Nuova Guinea 1
PH - Filippine 1
PS - Palestinian Territory 1
SI - Slovenia 1
SR - Suriname 1
TH - Thailandia 1
TN - Tunisia 1
TV - Tuvalu 1
Totale 6.058
Città #
Dallas 805
Singapore 425
Ashburn 206
Beijing 193
Moscow 108
Los Angeles 81
Ho Chi Minh City 73
Hong Kong 65
Milan 57
São Paulo 53
Munich 50
New York 46
The Dalles 45
Hefei 41
Rome 41
Boardman 37
Dublin 37
Istanbul 34
Warsaw 33
Florence 32
Hanoi 32
Pisa 31
Santa Clara 30
Lappeenranta 27
London 24
Beauharnois 23
Naples 22
Brooklyn 21
Council Bluffs 21
Helsinki 21
Houston 21
Montreal 21
Denver 20
Lucca 19
Rio de Janeiro 19
Buffalo 18
Genoa 18
Nuremberg 18
Orem 18
Chicago 16
Frankfurt am Main 16
Johannesburg 16
Mexico City 15
Phoenix 15
Stockholm 15
Tokyo 15
Chennai 14
Poplar 14
Atlanta 13
Boston 13
Seattle 13
Haiphong 12
Mumbai 12
Manchester 11
Amsterdam 10
Assago 10
Curitiba 10
Toronto 10
Belo Horizonte 9
Brescia 9
Paris 9
San Francisco 9
Tel Aviv 9
Turin 9
Turku 9
Cascina 8
Porto Alegre 8
Quito 8
Washington 8
Ankara 7
Bologna 7
Brussels 7
Charlotte 7
Goiânia 7
Guayaquil 7
Hải Dương 7
Livorno 7
Palermo 7
Brasília 6
Guangzhou 6
Redondo Beach 6
Santa Croce sull'Arno 6
Shanghai 6
Da Nang 5
Phủ Lý 5
Pittsburgh 5
Salt Lake City 5
Secaucus 5
Tashkent 5
Thái Nguyên 5
Vienna 5
Bad Vilbel 4
Bauru 4
Bexley 4
Biên Hòa 4
Casablanca 4
Caxias do Sul 4
Dhaka 4
Dongguan 4
Düsseldorf 4
Totale 3.400
Nome #
Left ventricular outflow tract velocity-time integral improves outcome prediction in patients with secondary mitral regurgitation 445
Trastuzumab cardiotoxicity and drug cardioprotection in healthy and cardiac dysfunction mouse models 324
Wild-type transthyretin cardiac amyloidosis is not rare in elderly subjects: the CATCH screening study 203
Echocardiography-Derived Forward Left Ventricular Output Improves Risk Prediction in Systolic Heart Failure 202
Atrial amyloidosis: mechanisms and clinical manifestations 200
Arrhythmic risk prediction in non-dilated left ventricular cardiomyopathy: The role of overlap with arrhythmogenic cardiomyopathy 185
Role of Imaging in Cardiomyopathies 176
Echocardiographic findings in subjects with an amyloidogenic apolipoprotein A1 pathogenic variant 174
Approccio critico all’interpretazione dei trial cardiovascolari con risultati neutri o negativi 170
Valvular heart disease in patients with cardiac amyloidosis 167
Disease features and management of cardiomyopathies in women 165
Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of Cardiology 164
Sex-specific associations of myocardial perfusion imaging with outcomes in patients with suspected chronic coronary syndrome 163
Haemodynamic forces predicting remodelling and outcome in patients with heart failure treated with sacubitril/valsartan 161
Multi-chamber speckle tracking imaging and diagnostic value of left atrial strain in cardiac amyloidosis 153
Clinical management of drug-induced cardiotoxicity in patients with HER-2+ breast cancer: current recommendations and future outlook 153
Valve disease in cardiac amyloidosis: an echocardiographic score 152
Cardiovascular toxicity from therapies for light chain amyloidosis 144
Use of new and emerging cancer drugs: what the cardiologist needs to know 143
Assessing cardiac mechanics through left ventricular haemodynamic forces 143
Estimated total amyloid burden from 18F-florbetaben positron emission tomography predicts all-cause mortality in light-chain cardiac amyloidosis 142
Management and treatment of cardiotoxicity due to anticancer drugs: 10 questions and answers 134
Etiological Treatment of Cardiac Amyloidosis: Standard of Care and Future Directions 132
Magnetic resonance imaging for diagnostic workup of embolic stroke of undetermined source: A systematic review 127
Estimated total amyloid burden from 18F-florbetaben positron emission tomography predicts all-cause mortality in light-chain cardiac amyloidosis 126
Exercise limitations in amyloid cardiomyopathy assessed by cardiopulmonary exercise testing—A multicentre study 126
Galectin-3 and Risk for Cancer or Heart Failure: Does Sex Matter? 123
Treatment Options in AF Patients with Cancer; Focus on Catheter Ablation 122
Exercise oscillatory ventilation in heart failure and brain–lung–heart–muscle crosstalk 111
Critical Reading of cardiovascular trials with neutral or negative results 110
Echocardiographic Estimate of Pulmonary Capillary Wedge Pressure Improves Outcome Prediction in Heart Failure Patients with Reduced and Mildly Reduced Ejection Fraction 110
Advancing Cardiovascular Risk Stratification and Functional Assessment: A Narrative Review of CPET and ESE Applications 108
Partial Lipodystrophy and LMNA p.R545H Variant 105
More cardiopulmonary effort testing needed in HFpEF! 104
Ischemic Heart Disease in Liver Transplant Candidates With High Bleeding Risk: Any Way Out? 100
Prevalence and clinical outcomes of isolated or combined moderate to severe mitral and tricuspid regurgitation in patients with cardiac amyloidosis 98
Post-acute cardiac complications following SARS-CoV-2 infection in partial lipodystrophy due to LMNA gene p.R349W mutation 94
The Mayo ATTR‐CM score versus other diagnostic scores and cardiac biomarkers in patients with suspected cardiac amyloidosis 93
Non-pegylated liposomal doxorubicin in older adjuvant early breast cancer patients: cardiac safety analysis and final results of the COLTONE study 91
Response to ‘Is the left atrium the key in the amyloid imaging lock?’ 78
Safety and Effectiveness of Sodium-Glucose Co-Transporter 2 Inhibitors in Active Cancer Patients with Heart Failure: Results of the Observational TOSCA Trial 57
null 29
Totale 6.107
Categoria #
all - tutte 28.733
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.733


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/202347 0 0 0 0 4 5 4 6 18 5 5 0
2023/2024246 1 0 48 34 10 22 30 8 6 16 14 57
2024/20252.115 40 48 85 51 121 122 291 414 200 149 276 318
2025/20263.699 379 726 859 941 619 175 0 0 0 0 0 0
Totale 6.107